Who Supplies Pemetrexed to India from CZECH REPUBLIC

To import finished pharmaceutical formulations containing Pemetrexed into India, the following regulatory requirements must be met:

1. Import License: Importers must obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT).

2. Product Registration: The product must be registered with the Central Drugs Standard Control Organisation (CDSCO). This involves submitting Form 40 or 41, along with necessary documents such as the Certificate of Pharmaceutical Product (CoPP), Good Manufacturing Practice (GMP) certificate, and stability data.

3. Approval Process: The approval process includes evaluation of the submitted documents, which may take several months.

4. No Objection Certificate (NOC): An NOC from the Ministry of Health and Family Welfare is required for the import of new drugs.

The timeline for obtaining CDSCO registration and NOC can vary but typically ranges from 6 to 12 months.

Imported pharmaceutical formulations containing Pemetrexed must undergo quality testing to ensure compliance with Indian standards:

1. Testing Requirements: Samples of each batch must be tested in a CDSCO-approved laboratory to verify quality, safety, and efficacy.

2. Certificate of Analysis (CoA): A CoA from the manufacturer, detailing the results of the quality tests, must accompany each shipment.

3. Stability Data: Stability studies must be conducted in accordance with International Council for Harmonisation (ICH) guidelines, specifically for Zone IV conditions, to ensure the product's stability in India's climate.

4. Indian Pharmacopoeia Standards: The formulations must comply with the standards set forth in the Indian Pharmacopoeia.

5. Port Inspection: Upon arrival, customs drug inspectors may conduct inspections to verify compliance with regulatory requirements.

Batch-wise testing and certification are mandatory for each import consignment.

Recent developments in India's import policies affecting finished pharmaceutical formulations include:

1. CDSCO Regulatory Updates: The CDSCO has implemented stricter guidelines for the import of new drugs, including more comprehensive documentation and longer approval timelines.

2. Production-Linked Incentive (PLI) Scheme: The PLI scheme, introduced to boost domestic manufacturing, may impact the import of certain pharmaceutical formulations by encouraging local production.

3. Bilateral Agreements: India has engaged in discussions with various countries, including the Czech Republic, to streamline import procedures and recognize mutual Good Manufacturing Practice (GMP) certifications.

These policy changes aim to enhance domestic manufacturing capabilities and ensure the quality of imported pharmaceutical products.

India imports finished Pemetrexed formulations primarily due to the following factors:

1. Patented Formulations: Certain Pemetrexed formulations are under patent protection, limiting domestic production and necessitating imports.

2. Specific Dosage Forms: Specialized dosage forms, such as injectable solutions, may not be manufactured domestically, leading to import reliance.

3. Market Size: The oncology market in India is substantial, with a growing demand for effective cancer treatments, including Pemetrexed-based therapies.

The exact market size for Pemetrexed formulations in India is not specified in the available data.

The import duty and customs structure for finished pharmaceutical formulations containing Pemetrexed (HS Code 30049049) are as follows:

1. Basic Customs Duty (BCD): 10% of the Cost, Insurance, and Freight (CIF) value.

2. Social Welfare Surcharge (SWS): 10% of the BCD, amounting to 1% of the CIF value.

3. Integrated Goods and Services Tax (IGST): Applicable as per prevailing rates, calculated on the total of CIF value, BCD, and SWS.

4. Anti-Dumping Duty: Not specified in the available data.

5. Exemption Notifications: Specific exemptions or concessional duties for imports from the Czech Republic are not specified in the available data.

The total landed duty percentage is calculated by summing the BCD, SWS, and IGST.

India sources finished Pemetrexed formulations from the Czech Republic due to several competitive advantages:

1. Patents: The Czech Republic may hold patents for certain Pemetrexed formulations, making them exclusive sources.

2. Specialized Dosage Forms: The country may offer specialized dosage forms not available from other suppliers.

3. Quality: Manufacturers in the Czech Republic are known for adhering to high-quality standards, ensuring product efficacy and safety.

Other suppliers, such as China, Germany, and the United States, also export Pemetrexed formulations to India. However, the Czech Republic's share in this market segment is not specified in the available data.

India imports finished Pemetrexed formulations from the Czech Republic due to strategic reasons:

1. Patented Formulations: The Czech Republic may offer patented Pemetrexed formulations not available elsewhere.

2. Specialized Dosage Forms: Unique dosage forms, such as specific injectable solutions, may be sourced from the